title: [Nab-paclitaxel].
abstract: Paclitaxel is conventionally used in a wide range of oncology indications. Nab-paclitaxel is synthesized by a process of high pressure homogenization of paclitaxel in the presence of human albumin and it was originally developed to reduce the toxicity usually associated with cremophor in soluble paclitaxel and to increase its penetration in tumor tissues. After the trials that led to its approval in first-line treatment of metastatic pancreatic carcinomas and in second line therapy for metastatic breast cancer, nab-paclitaxel is being tested for many other situations in oncology due to its profile of security and its good tolerance. Different lines of research are being developed about the possible biomarkers that could predict the effect of nab-paclitaxel. This review summarizes the results of trials that led to the approval of the nab-paclitaxel in advanced breast cancer and pancreatic cancer, and also resumes the lines of research to the future development of the drug.
authors.affiliation: Université Pierre-et-Marie-Curie Paris VI (UPMC), hôpital Saint-Antoine, service d'oncologie médicale, 184, rue Faubourg-Saint-Antoine, 75012 Paris, France. Electronic address: daniel.lopez-trabada-ataz@sat.aphp.fr.
authors.forename: Daniel
authors.initials: D
authors.lastname: Lopez-Trabada Ataz
authors.affiliation: Université Pierre-et-Marie-Curie Paris VI (UPMC), hôpital Saint-Antoine, service d'oncologie médicale, 184, rue Faubourg-Saint-Antoine, 75012 Paris, France.
authors.forename: Sarah
authors.initials: S
authors.lastname: Dumont
authors.affiliation: Université Pierre-et-Marie-Curie Paris VI (UPMC), hôpital Saint-Antoine, service d'oncologie médicale, 184, rue Faubourg-Saint-Antoine, 75012 Paris, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: André
mesh_terms: D000418:Albumins / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D005260:Female; D005602:France; D006801:Humans; D020360:Neoadjuvant Therapy; D009363:Neoplasm Proteins / Q000378:metabolism; D015676:Osteonectin / Q000378:metabolism; D017239:Paclitaxel / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011379:Prognosis
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D000972:Antineoplastic Agents, Phytogenic; D009363:Neoplasm Proteins; D015676:Osteonectin; C577241:SPARC protein, human; D017239:Paclitaxel
keywords: Adénocarcinome pancréas; Breast cancer; Cancer du sein; Nab-paclitaxel; Paclitaxel; Pancreatic adenocarcinoma; Protéine SPARC; SPARC protein